CLL

Social distancing measures are keeping people apart, but that hasn't stopped some patients with CLL from finding a new sense of community.

The COVID-19 Pandemic has changed immediate treatment for patients with chronic lymphocytic leukemia, but it is also impacting the clinical trials looking to improve the future treatment for these patients.

Dr. Richard Pazdur, director of the Food and Drug Administration’s Oncology Center of Excellence, has noted that the agency is committed to expediting oncology drug development despite the challenges posed by the COVID-19 pandemic.

The Food and Drug Administration, under its global Project Orbis, approved the combination of Imbruvica and Rituxan for patients with CLL and SLL.

Calquence (acalabrutinib) may be a safe and effective treatment option for patients with relapsed or refractory chronic lymphocytic leukemia, according to the updated phase 2 results of an ongoing study.

First validated prognostic score offers valuable insights for patients with chronic lymphocytic leukemia who are prescribed active surveillance.

Bruton tyrosine kinase (BTK) inhibitors and other new drugs are improving outcomes for patients with CLL.

The COVID-19 pandemic's impact is being felt all throughout the cancer community, and experts from the CLL Society hosted a webinar to discuss the specific impacts of the pandemic on patients with chronic lymphocytic leukemia.

Patients with relapsed or refractory CD19-positive cancers experienced complete responses with no major side effects following treatment with CAR-NK cell therapy.

Newer medications that displace chemotherapy aim directly at mutations in the Bruton tyrosine kinase gene and help patients with CLL live longer.

The novel drug pairing of Venclexta and Gazyva, used for a fixed 12 months, is cost-effective compared with regimens that must be taken until disease progresses, a study finds.